Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii

Area of Science:

• Infectious Diseases
• Microbiology
• Pharmacology

Background:

• Acinetobacter baumannii-calcoaceticus complex (ABC) causes severe hospital-acquired and ventilator-associated bacterial pneumonia.
• Multidrug-resistant ABC strains are a significant threat, often exhibiting resistance to existing antibiotics.
• Sulbactam, a penicillin derivative, has activity against Acinetobacter but is susceptible to hydrolysis by bacterial beta-lactamases.

Purpose of the Study:

• To evaluate the efficacy of sulbactam-durlobactam for treating bacterial pneumonia caused by susceptible ABC isolates.
• To highlight the role of durlobactam in overcoming beta-lactamase-mediated resistance in Acinetobacter infections.

Main Methods:

• Sulbactam-durlobactam is a pathogen-targeted combination therapy approved by the US FDA.
• Durlobactam acts as a beta-lactamase inhibitor, targeting Ambler classes A, C, and D serine beta-lactamases.
• The combination restores sulbactam's activity against multidrug-resistant ABC both in vitro and in vivo.

Main Results:

• Sulbactam-durlobactam demonstrates efficacy in treating serious Acinetobacter infections.
• The drug combination is approved for hospital-acquired and ventilator-associated bacterial pneumonia in adults.
• It provides a promising therapeutic option for infections caused by susceptible ABC isolates.

Conclusions:

• Sulbactam-durlobactam represents a significant advancement in treating challenging Acinetobacter baumannii infections.
• The drug combination offers a viable alternative for patients with limited treatment options due to multidrug resistance.
• Effective management of ABC infections is crucial due to their high mortality rates.